Paper Details

  1. Home
  2. Paper Details

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Author: AndersonR, BondM, DavisS, HoyleM, HydeC, JeffreysM, MinersA, MoxhamT, PetersJ, RogersG, ThokalaP, WailooA

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Acetylcholinesterase inhibitors (AChEIs) are likely cost-saving for mild-to-moderate Alzheimer’s disease, with donepezil being the most cost-effective. Memantine’s cost-effectiveness is less certain.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Alzheimer’s disease (AD) is the most commonly occurring form of dementia. It is predominantly a disease of later life, affecting 5% of those over 65 in the UK. OBJECTIVES: Review and update guidance to the NHS in England and Wales on the clinical effectiveness and cost-effectiveness of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780923/

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Alzheimer's Disease Treatment: A Cost-Effective Approach

Alzheimer’s disease, like a vast and unforgiving desert, is a complex and challenging condition. The search for effective and cost-effective treatments is ongoing, like a tireless caravan seeking a reliable route through the desert. This systematic review, like a seasoned guidebook, evaluates the effectiveness and cost-effectiveness of various medications used to treat Alzheimer’s disease. The researchers, like explorers charting a new path, seek to identify the most promising strategies for managing this devastating disease.

Cost-Effective Treatment Strategies: A Balanced Approach to Care

The review examines the cost-effectiveness of donepezil, galantamine, rivastigmine, and memantine in treating Alzheimer’s disease. The researchers find that these drugs, like a well-equipped caravan, can provide clinical benefits and potentially reduce costs compared to best supportive care. However, they also acknowledge the need for further research to solidify these findings and explore the long-term impact of these treatments.

The Journey Ahead: Navigating the Sands of Research

This review serves as a valuable roadmap for navigating the complexities of Alzheimer’s disease treatment. It emphasizes the importance of a balanced approach that considers both clinical effectiveness and cost-effectiveness. The researchers highlight the need for continued research to better understand the long-term impact of these treatments and develop even more effective and affordable options for patients.

Dr.Camel's Conclusion

The desert of Alzheimer’s disease is vast and complex. This review provides valuable insights into the current landscape of treatment options, emphasizing the importance of both clinical effectiveness and cost-effectiveness. Further research is crucial to refine our understanding of this disease and develop even more effective treatments.

Date :
  1. Date Completed 2012-09-11
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

22541366

DOI: Digital Object Identifier

PMC4780923

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.